Other Information.
+Added: Adoption or Termination of 10b5-1 Trading Plans
+Added: On May 9, 2024 , William Chou , M.D., a director and officer of the Company , terminated a pre-arranged written stock sale plan in accordance with Rule 10b5-1 under the Exchange Act, for the potential sale of up to 300,000 shares of the Company’s common stock.
+Added: The plan was terminated in accordance with the Company’s policies regarding transactions in the Company’s securities.
+Added: The plan was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act and was scheduled to terminate no later than August 30, 2024 , or on such earlier date on which all of the trades thereunder had been executed.
+Added: Other than as disclosed above, during the fiscal quarter ended June 30, 2024, none of the Company’s directors or officers adopted or terminated any “Rule 10b5-1 trading arrangements” or any “non-Rule 10b5-1 trading arrangements,” as each term is defined in Item 408 of Regulation S-K.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
Filed/Furnished
−Removed: Non-Employee Director Compensation Policy effective as of April 4, 2024
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
19 unchanged sentences
PASSAGE BIO, INC.
+Added: August 8, 2024
/s/ William Chou, M.D.
1 unchanged sentence
President and Chief Executive Officer
+Added: August 8, 2024
/s/ Kathleen Borthwick
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.